XIG: FHIR Resources

FHIR IG Statistics: FHIR Resources

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | BNW | au | be | br | ca | ch | cl | cr | cz | de | dk | ee | eu | fi | fr | il | in | it | jp | kr | nl | no | nz | pl | se | sl | stt | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - ValueSet

29,056 resources

By Version

R2: 0
R2B: 0
R3: 1,154
R4: 23,662
R4B: 244
R5: 3,968
R6: 28

By Authority

none: 8,611
hl7: 17,881
ihe: 218
national: 1,286
who: 1,060

By Realm

none: 5,874
au: 87
be: 108
br: 73
ca: 244
ch: 395
cl: 150
cr: 11
cz: 48
de: 680
dk: 475
ee: 66
eu: 349
fi: 4
fr: 810
il: 144
in: 48
it: 92
jp: 71
nl: 958
no: 6
nz: 17
pl: 23
se: 10
tw: 161
uk: 23
us: 13,139
uv: 4,925
vn: 23
other: 5

Start Prev Rows 5000 - 5200 Next

Package	Version	Identity	Name/Title	Status	Date	Realm	Auth
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.260	Rivaroxaban Anticoagulant	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.262	Fondaparinux Anticoagulant	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.263	Dalteparin Anticoagulant	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.264	Heparin	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.268	Enoxaparin Anticoagulant	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.271	Undetectable Lab Result Value	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.272	Undetectable Lab Result Value	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.274	Dietary Recommendations	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.275	Bariatric Procedures	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.276	Telemedicine Services	active	2025-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.277	Prostate Cancer Treatment	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.28	Traumatic Avulsion of Kidney	active	2022-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.29	Rapidly Progressive Nephritic Syndrome	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.301	LDL Cholesterol	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.33	Obstetrics and VTE Obstetrics	active	2022-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.34	Glucose Lab Test Mass Per Volume	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.349	Tuberculosis for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.350	Tuberculosis for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.351	Tuberculosis for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.352	Androgen Deprivation Therapy for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.353	Bacillus Calmette Guerin for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.354	Bladder Cancer for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.355	Chemotherapy Agents for Advanced Cancer	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.356	Cystectomy for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.357	Cystectomy for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.358	Cystectomy for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.359	DEXA Bone Density for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.360	Hospital Services for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.361	Immunocompromised Conditions	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.362	Immunocompromised Conditions	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.363	Immunocompromised Conditions	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.364	Immunosuppressive Drugs for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.365	Mixed Histology Urothelial Cell Carcinoma for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.366	Morbid Obesity	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.367	Morbid Obesity	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.368	Morbid Obesity	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.369	Unavailability of Bacillus Calmette Guerin for Urology Care	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.370	Urinary Retention	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.371	Urinary Retention	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.372	Urinary Retention	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.374	Face to Face Interaction	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.375	Face to Face Interaction	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.376	HIV Viral Load Tests	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.377	HIV Viral Load Tests	active	2025-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.389	Syphilis Tests	active	2025-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.4	Nephrectomy	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1248.8	Large Body Surface Area (BSA) Burns	active	2022-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1250.2	Psychological Neuropsychological or Neurobehavioral Testing	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1250.3	Psychological or Neuropsychological Testing	active	2023-11	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1251.10	Tricuspid Valve Regurgitation	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1251.2	Valvular Heart Disease	active	2022-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1258.1	Gonorrhea Screening	active	2025-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1258.2	Abnormal Weight Loss	active	2024-10	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.2	Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.3	Prescribable brand and generic insulins and analogues	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.4	eGFR Using 2021 Race Free Formulas	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.5	Fructosamine in Serum or Plasma	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.6	Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.7	Creatinine in serum/plasma	active	2023-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1259.9	IgE Agonists, prescribable	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.10	Estrogen Receptor Testing for Orserdu	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.100	MMR Proficient	active	2024-01	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.101	Systemic Cancer Directed Therapy	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.102	Face To Face Interaction	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.104	Erdafitinib	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.107	Chemotherapy Encounter	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.108	Urothelial Cancers ICD9	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.109	Urothelial Cancer ICD10	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.110	Urothelial Cancers	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.111	Prior Therapies for Erdafitinib	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.112	Urothelial Cancer Histologies	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.113	Malignant Tumor Behavior	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.114	Localized Bladder Cancer Stage SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.116	Localized Bladder Cancer Staging	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.117	Advanced Bladder Cancer Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.118	Localized Bladder Cancer T Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.119	Localized Bladder Cancer T Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.120	Localized Bladder Cancer N Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.121	Localized Bladder Cancer M Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.122	Advanced Bladder Cancer M Stage	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.124	Locoregional Urothelial Cancer ICD9	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.125	Locoregional Urothelial Cancer ICD10	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.126	Locoregional Urothelial Cancer SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.127	Locoregional Urothelial Cancer	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.128	FGFR3 Gene	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.129	FGFR3 Gene Interpretation Positive SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.130	FGFR3 Gene Interpretation Positive LOINC	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.131	FGFR3 Gene Interpretation Positive NCI	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.133	FGFR3 Gene Interpretation Positive	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.134	FGFR3 Gene Interpretation Negative SNOMED	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.135	FGFR3 Gene Interpretation Negative NCI	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.137	FGFR3 Gene Interpretation Negative	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.138	FGFR3 Molecular Variants	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.139	Tumor Behavior	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.140	Physcological Support for Cancer	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.141	Referral For Pain From Cancer	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.142	Cancer Pain Education	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.143	Telehealth Encounters	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.144	Pain Assessment Score	active	2024-02	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.146	Telehealth Encounters SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.147	Telehealth Encounters CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.148	Telehealth Encounters HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.149	Telehealth Encounters All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.150	Chemo Admin SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.151	Chemo Admin CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.152	Chemo Admin HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.153	Chemotherapy Administration All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.154	Radiation Treatment CPT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.155	Radiation Treatment HCPCS	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.156	Radiation Treatment SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.157	Radiation Treatment All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.158	Bipolar Diagnosis Codes	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.159	Telephone Visits SNOMED	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.160	Telephone Visit CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.161	Telephone Visits All	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.162	Adolescent depression screening assessment	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.163	Adult depression screening assessment LOINC	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.165	Referral for Depression Adult	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.166	Referrals for Adolescent Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.167	Follow Ups for Adolescent Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.168	FollowUps for Adult Depression	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.169	Depression Screen Declined for Medical Reason	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.170	Physical Therapy Evaluations SNOMEDCT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.171	Physical Therapy Evaluation CPT	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.172	Physical Therapies Evaluations	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.173	Non Opioid Analgesics	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.174	Adjuvant Analgesics	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.176	Lung Cancer ICD9	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.177	Lung Cancer ICD10	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.178	Lung Cancer	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.179	Prior Therapies for Osimertinib	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.18	Stage IA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.181	Plan of Care for Pain	active	2024-03	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.182	All Antineoplastic Agents	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.183	Locally Advanced NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.185	Localized NSCLC Stage Group SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.186	Radiation Treatment Management	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.187	Plan of Care	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.188	Documentation of Plan of Care	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.189	Pain Present	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.19	Stage IB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.190	Localized NSCLC Stage Group NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.192	Localized NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.193	Advanced NSCLC Stage Group	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.194	NSCLC M Stage (metastatic)	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.195	NSCLC T Stage	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.196	NSCLC N Stage	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.197	SCLC and rarer lung cancer histology	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.198	EGFR Gene	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.199	EGFR Gene Interpretation Positive SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.20	Stage IIA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.200	EGFR Gene Interpretation Positive LOINC	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.201	EGFR Gene Interpretation Positive	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.202	EGFR Osimertinib Molecular Variants	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.203	EGFR Generic Molecular Variant NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.204	EGFR Generic Molecular Variant SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.205	EGFR Generic Molecular Variant LOINC	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.206	EGFR Molecular Variants Osimertinib PM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.207	Osimertinib	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.208	Pemetrexed	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.209	Radiation Treatment Management SNOMEDCT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.21	Stage IIB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.210	Radiation Treatment Management Codes	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.211	Radiation Treatment Delivery CPT	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.212	77427 Management Code	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.213	Radiation Treatment Delivery HCPCS	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.214	Radiation Treatment Delivery NCIM	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.215	Radiation Treatment Delivery SNOMED	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.216	Radiation Treatment Delivery	active	2024-04	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.217	MET Gene Test	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.219	Tepotinib	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.22	Stage IIIA	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.220	MET Positive gene interpretation	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.227	MET Exon 14 skipping molecular variant	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.23	Stage IIIB	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.233	test43	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.234	ROS1 Molecular Variants Repotrectinib PM	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.235	ROS1 Repotrectinib Molecular Variants	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.236	ROS1 Negative (geneinterpretation) SNOMEDCT	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.237	ROS1 Negative (geneinterpretation) NCI	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.238	ROS1 Negative (geneinterpretation) SNOMEDCT,NCI	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.239	ROS1 Positive (geneinterpretation)	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.24	Stage IIIC	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.240	ROS1 results (HGNC)	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.241	ROS1 Gene Rearrangement	active	2024-05	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.246	RET Negative (geneinterpretaion) NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.247	RET Negative (geneinterpretaion) SNOMEDCT,NCI	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.248	RET Fusion Molecular Variants	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.25	ESR1 Gene Test	active	2023-08	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.250	Repotrectinib Value set	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.251	Amivantamab	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.252	Alectinib Drug	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.253	Gemcitabine Drug Value set	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.254	vinorelbine Drug	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.255	NSCLC_Tumor_resection SNOMEDCT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.256	NSCLC_Tumor_resection CPT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.257	NSCLC_Tumor_resection SNOMEDCT CPT	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.258	ALK results (HGNC)	active	2024-07	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.259	ALK Positive (geneinterpretation) SNOMED	active	2024-06	us	hl7
us.nlm.vsac	R4	ValueSet/2.16.840.1.113762.1.4.1260.26	ESR1 Genetic Mutation	active	2023-08	us	hl7